AJNR Am J Neuroradiol

1. OKUDA DT, Punnen TG, Moog TM, McCreary MC, et al
   Understanding the Therapeutic Impact of Disease-Modifying Therapies or No Treatment on Enlarging T1-Weighted Hypointense Lesions and Total T1-Weighted Hypointense Lesion Volume in MS.
   AJNR Am J Neuroradiol. 2026;47:843-851.
   

   >> Share

   
   

   
   Arch Phys Med Rehabil

2. BPHTY TR, Hillier S, Serrada I, Gerges A, et al
   Group vs Individual Therapy for Neurological Recovery: A Systematic Review and Meta-Analysis.
   Arch Phys Med Rehabil. 2025 Aug 27:S0003-9993(25)00868.
   

   >> Share

   
   

   
   BMC Neurol

3. MACHADO A, Dervish J, Friberg E
   Employment status and self-rated health in people with multiple sclerosis in Sweden.
   BMC Neurol. 2026 Mar 11. doi: 10.1186/s12883-026-04809.
   

   >> Share

   
   

   
   Brain

4. CORAZZOLLA G, Treaba CA, Mohammadian M, Brusaferri L, et al
   Evidence of skull bone translocator protein overexpression linked to multiple sclerosis progression.
   Brain. 2026 Mar 9:awag084. doi: 10.1093.
   

   >> Share

   
   

   
   J Clin Invest

5. LEE-CHANG C
   Organized immunity in the CNS: what stroke reveals about neuroinflammation and lymphoid niches.
   J Clin Invest. 2026;136:e202688.
   

   >> Share

   
   

   
   J Neuroimmunol

6. ATASEVER U
   Bile acid-microbiota interactions in multiple sclerosis: From experimental models to early clinical evidence.
   J Neuroimmunol. 2026;415:578898.
   

   >> Share

   
   
7. DAMSBO K, Reyahi A, Nik AM, Oubounyt M, et al
   Astrocyte-specific FoxF2 modulates immune and myelin repair: Evidence from multiple sclerosis lesions and an animal model.
   J Neuroimmunol. 2026;415:578896.
   

   >> Share

   
   
8. SARIN S, Modak N, Sun R, Subei O, et al
   Predicting the final clinical phenotype after the first attack of optic neuritis.
   J Neuroimmunol. 2023;381:578130.
   

   >> Share

   
   

   
   J Neurol

9. BERGAMASCHI R, Ferraro OE, Enrico P, Marzia F, et al
   Ozone pollution as a possible trigger for multiple sclerosis in young people: the PEDIGREE study.
   J Neurol. 2026;273:172.
   

   >> Share

   
   
10. KLEIN KRANENBARG RAM, Blok KM, van Hasselt Y, Melisse S, et al
    Symptoms of depression and anxiety are early predictors of multi-domain disability progression in progressive MS.
    J Neurol. 2026;273:182.
    

    >> Share

    
    
11. MOLENAAR PCG, de Jong DJ, Hof SN, van Oirschot P, et al
    Digital monitoring of disease activity in relapsing-remitting multiple sclerosis.
    J Neurol. 2026;273:186.
    

    >> Share

    
    
12. FREEDMAN DE, Benedict RHB, Oh J, Feinstein A, et al
    The non-linear relationship between self-reported cognitive concerns and performance-based cognitive dysfunction in people with multiple sclerosis: a cross-sectional study.
    J Neurol. 2026;273:190.
    

    >> Share

    
    
13. CANDELORO R, Laudisi M, Ferri C, Baldi E, et al
    Beyond oligoclonal bands: the independent role of kappa free light chains in the diagnostic workup of multiple sclerosis.
    J Neurol. 2026;273:191.
    

    >> Share

    
    
14. DIMITRIADOU EM, Tzanetakos D, Theodorou A, Akrivaki A, et al
    The predictive value of serum neurofilament light chain in achieving no evidence of disease activity-3 (NEDA-3) status in treatment-naive patients with multiple sclerosis.
    J Neurol. 2026;273:194.
    

    >> Share

    
    
15. GUERRA T, Lucisano G, Rocca MA, Cocco E, et al
    HerMeS: a registry-based evaluation of the HERCULES criteria for identifying nonrelapsing SPMS.
    J Neurol. 2026;273:193.
    

    >> Share

    
    

    
    J Neurol Sci

16. RICAURTE-FAJARDO A, Garcia Gonzalez K, Merino Campo S, Alvarado-De la Hoz C, et al
    Integrated determinants of multiple sclerosis susceptibility: Genetics, environment, infection and the microbiota.
    J Neurol Sci. 2026;484:125865.
    

    >> Share

    
    
17. IANNIELLO A, Piervincenzi C, Pozzilli C, Satriano F, et al
    A proof-of-concept study on the relationship between lifetime Estrogen exposure, menopausal transition, and neurodegeneration in women with multiple sclerosis.
    J Neurol Sci. 2026;484:125854.
    

    >> Share

    
    

    
    Mult Scler

18. SIVA A, Kantarci O
    Multiple sclerosis controversies: Do MRI-negative relapses really exist? - Commentary.
    Mult Scler. 2026 Mar 3:13524585261423082. doi: 10.1177/13524585261423082.
    

    >> Share

    
    
19. ABAD-INCHAURRONDO I, Lu S, Lui E, Susin-Calle S, et al
    Performance of the 2024 McDonald diagnostic criteria for multiple sclerosis.
    Mult Scler. 2026 Mar 3:13524585261421816. doi: 10.1177/13524585261421816.
    

    >> Share

    
    
20. CORONA A, Clarelli F, Paakkonen K, Harroud A, et al
    Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.
    Mult Scler. 2026 Mar 3:13524585261417130. doi: 10.1177/13524585261417130.
    

    >> Share

    
    
21. SPAGNOLO F, Gordaliza PM, Bhardwaj A, Lu PJ, et al
    A multi-modal deep learning network for the classification of paramagnetic rim and remyelinated lesions in multiple sclerosis.
    Mult Scler. 2026 Mar 6:13524585261421491. doi: 10.1177/13524585261421491.
    

    >> Share

    
    
22. EBRAHIMI A, Wiil UK, Olsson T, Lio P, et al
    A susceptibility network analysis of disease trajectories leading to multiple sclerosis: A nationwide cohort study.
    Mult Scler. 2026 Mar 10:13524585261421480. doi: 10.1177/13524585261421480.
    

    >> Share

    
    
23. NOVA A, Di Caprio G, Gentilini D, Bernardinelli L, et al
    A bidirectional two-sample Mendelian randomization study of immune responses against Epstein-Barr virus nuclear antigen 1 and multiple sclerosis in individuals of European ancestry.
    Mult Scler. 2026 Mar 10:13524585261423063. doi: 10.1177/13524585261423063.
    

    >> Share

    
    
24. INOJOSA H, Mathias R, Dillenseger A, Voigt I, et al
    AI-enabled Living Labs: Accelerating innovation in multiple sclerosis care and research.
    Mult Scler. 2026 Mar 13:13524585261424136. doi: 10.1177/13524585261424136.
    

    >> Share

    
    

    
    Nat Rev Neurol

25. GRIMSEY B
    We need to talk about risk in multiple sclerosis.
    Nat Rev Neurol. 2026;22:137.
    

    >> Share

    
    

    
    Nervenarzt

26. KLIMAS R, Karl AS, Poser PL, Sgodzai M, et al
    [Over one year of B?cell targeted therapy with Ofatumumab s.c.: first results of a prospective, patient-centered real-world observational study].
    Nervenarzt. 2023;94:923-933.
    

    >> Share

    
    

    
    Neurol Clin Pract

27. BOVE R, Simoni M, Castelo-Branco C, Correale J, et al
    Expert Opinion on Age-Related Sex Hormone Changes and Hypogonadism in People With Multiple Sclerosis: A Delphi Consensus Program.
    Neurol Clin Pract. 2026;16:e200588.
    

    >> Share

    
    

    
    Neurology

28. KIM SH, Lee EJ, Lim YM, Kim H, et al
    Prevalence and Relative Proportions of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the Republic of Korea.
    Neurology. 2026;106:e214792.
    

    >> Share

    
    
29. JACOBS BM, Schalk L, Tregaskis-Daniels E, Scalfari A, et al
    Genetic Determinants of Multiple Sclerosis Susceptibility in People From Diverse Ancestral Backgrounds.
    Neurology. 2026;106:e214708.
    

    >> Share

    
    
30. MARTINEZ SOSA S, Tisavipat N, Betting T, Guo Y, et al
    Pearls & Oy-sters: Using Susceptibility-Based Imaging in Highly Active Late-Onset Multiple Sclerosis.
    Neurology. 2026;106:e214794.
    

    >> Share

    
    

    
    PLoS One

31. GIORDANO A, De Panfilis L, Zagarella RM, Di Domenico G, et al
    Communication competences of multiple sclerosis neurologists during advance care planning conversations: A multi-observer study.
    PLoS One. 2026;21:e0336183.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

32. LUM FM, Sattarnezhad N, Ho PP, Orr N, et al
    Multiple molecular mimics in Epstein Barr Nuclear Antigen-1, and the pathogenesis of multiple sclerosis.
    Proc Natl Acad Sci U S A. 2026;123:e2519445123.
    

    >> Share

    
    
33. CHIA PHJ, Toyonaga T, Tong J, Le H, et al
    SV2A PET reveals synaptic density loss in experimental autoimmune encephalomyelitis and in a pilot multiple sclerosis study.
    Proc Natl Acad Sci U S A. 2026;123:e2517709123.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share